Benjamin Amberg, NP
Family · Lexington, SCNPI 1528545597
Payments from drug & device makers
Across 213 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$614
- Lilly USA, LLC$375
- Pfizer$302
- Novo Nordisk$290
- Abbott$228
- Dexcom, Inc.$208
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,591100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $614 |
| Lilly USA, LLC | 25 | $375 |
| Pfizer | 17 | $302 |
| Novo Nordisk | 18 | $290 |
| Abbott | 12 | $228 |
| Dexcom, Inc. | 8 | $208 |
| AstraZeneca(2 entities) | 13 | $185 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $155 |
| GSK | 10 | $150 |
| Amgen | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $90 |
| Exact Sciences | 5 | $81 |
| Dynavax Technologies Corporation | 4 | $80 |
| Novartis | 3 | $70 |
| Daiichi Sankyo Inc. | 3 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $49 |
| Merck | 3 | $44 |
| Stryker | 1 | $39 |
| Bayer | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Boehringer Ingelheim | 2 | $27 |
| Inari Medical, Inc. | 1 | $23 |
| Insulet Corporation | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Edwards Lifesciences | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Cvrx, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$3,603 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 95 | $164,165 |
| MounjaroTirzepatide | 71 | $102,056 |
| TrulicityDulaglutide | 36 | $60,374 |
| EliquisApixaban | 39 | $45,577 |
| JanuviaSitagliptin Phosphate | 33 | $39,598 |
| JardianceEmpagliflozin | 16 | $24,556 |
| XareltoRivaroxaban | 15 | $22,058 |
| FarxigaDapagliflozin Propanediol | 26 | $21,792 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $18,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $15,118 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $13,128 |
| LinzessLinaclotide | 14 | $9,634 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $5,308 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 213 | $4,796 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $4,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $290 | $164,16595 claims |
| Lilly USA, LLCMounjaro, Trulicity | $375 | $162,429107 claims |
| PfizerEliquis | $302 | $45,57739 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $185 | $40,60652 claims |
| MerckJanuvia | $44 | $39,59833 claims |
| Boehringer IngelheimJardiance | $27 | $24,55616 claims |
| Johnson & JohnsonXarelto | $16 | $22,05815 claims |
| GSKTrelegy Ellipta | $150 | $15,11813 claims |
| AbbVieLinzess, Synthroid | $614 | $10,83034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.
Other family in Lexington
- Amy LoperLexington$20K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.